Gynecologic Oncology Reports (Nov 2021)
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
- Alessandra Vultaggio,
- Maria Cristina Petrella,
- Federica Tomao,
- Francesca Nencini,
- Valentina Mecheri,
- Andrea Marini,
- Margherita Perlato,
- Emanuele Vivarelli,
- Claudia De Angelis,
- Ilaria Ferrarini,
- Serena Pillozzi,
- Andrea Matucci,
- Lorenzo Antonuzzo
Affiliations
- Alessandra Vultaggio
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
- Maria Cristina Petrella
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
- Federica Tomao
- Department of Gynecologic Oncology, European Institute of Oncology (IEO), IRCSS, Milan, Italy
- Francesca Nencini
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
- Valentina Mecheri
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
- Andrea Marini
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
- Margherita Perlato
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
- Emanuele Vivarelli
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
- Claudia De Angelis
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
- Ilaria Ferrarini
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
- Serena Pillozzi
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
- Andrea Matucci
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy; Corresponding author at: Immunoallergology Unit, Careggi University Hospital, Florence 50134, Italy.
- Lorenzo Antonuzzo
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- Journal volume & issue
-
Vol. 38
p. 100880